1800 202 8726
Understanding your biopsy result

Atypical, Borderline and Premalignant: — What Your Biopsy Result Actually Means

Getting a biopsy result that uses words like atypical, borderline or premalignant can feel like no answer at all. These are not cancer diagnoses — but they are not normal results either. This page explains what each term means and what should happen next.

Medically reviewed by Dr. C. Raghavendra Reddy, Medical Oncologist, MBBS (Gold Medal) · DNB · DM (Medical Oncology, Gold Medal) · Last reviewed September 2026

  • Not cancer — but not nothing — These terms describe cells that have changed but have not crossed into malignancy.
  • The organ always matters — The same word can carry different weight depending on where in the body the result comes from.
  • Some carry a progression risk — A proportion of these findings can develop into cancer over time — your doctor will explain what applies to you.
  • Many are caught at the right moment — Detection at this stage is often what makes effective intervention possible.
4.8 · 800+ Google reviews · 15,000+ patients treated
Limited Slots Today

Talk to a medical oncologist

₹950   Today: FREE  ·  Including free written second opinion

Reply within 2 working hours
Report reviewed by a senior oncologist
Confidential. No commitment to start treatment.
or
Call 1800 202 8726
17+
Cancer Specialists
on Panel
96.9%
Breast Cancer
Survival Rate*
15,000+
Patients
Treated
4.8★
Google Rating
(800+ reviews)

Words like atypical, borderline and premalignant in a biopsy report do not mean you have cancer. They describe cells that have changed but have not crossed into malignancy. Some carry a risk of progressing over time — not all do. Your specialist will explain what your specific finding means and what should happen next.

Are these results cancer?

No. These terms describe a zone between normal cells and cancer — abnormal enough to be significant, but not meeting the criteria for a malignant diagnosis.

That is not the same as reassurance. The finding sits in a category that carries its own risks and its own need for follow-up, and the specific wording matters more than the general category.

You are being told that something has changed, that the change is significant enough to track, and that what comes next depends on exactly which finding you have and where it is in the body.

What to do now

  • Ask your doctor to name the exact finding and explain what it means for that specific organ — not just the general category.
  • Write down the exact wording from your pathology report and bring it to every future appointment.
  • Ask whether further testing is needed before your management plan is finalised.
  • Tell your doctor about any herbal, ayurvedic or traditional medicines you are taking.
  • Ask when your next review is, what it will involve, and what should prompt you to call earlier.
  • Ask for your pathology report in writing if you have not already received it — you are entitled to it.

What is the risk that this will become cancer?

The risk varies considerably depending on the exact finding, the organ, the grade of change, and your individual factors. There is no single number that applies across all these results.

Guidance from bodies including NCCN, ESMO and ICMR is consistent in showing that many premalignant and borderline findings do not progress — particularly when detected and followed appropriately. But population-level statements do not describe any individual result.

Your specialist will tell you which risk category your finding falls into. That is the only figure that should inform your decisions.

Not sure what this means for you?

Share your reports and a senior oncologist will explain your options in plain language — no obligation to start treatment.

Meet the Specialists

17+ senior cancer specialists. One panel for your case.

Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.

Dr. Naresh Gundu
Medical Oncologist

Dr. Naresh Gundu

MBBS, DNB (Internal Medicine), DM (Medical Oncology)

View Profile
Dr. C. Raghavendra Reddy
Medical Oncologist

Dr. C. Raghavendra Reddy

MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)

View Profile
Dr. Bharati Devi Gorantla
Medical Oncologist

Dr. Bharati Devi Gorantla

MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)

View Profile
Dr. Owais Mohammed
Medical Oncologist

Dr. Owais Mohammed

MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)

View Profile
Dr. T. Raghavender Reddy
Medical Oncologist

Dr. T. Raghavender Reddy

MBBS, DM (Medical Oncology), MD (Radiation Oncology)

View Profile
Dr. N. Kiranmayee
Medical Oncologist

Dr. N. Kiranmayee

MBBS, DM (Medical Oncology), MD (Internal Medicine)

View Profile
Dr. Muralidhar Muddusetty
Surgical Oncologist

Dr. Muralidhar Muddusetty

MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)

View Profile
Dr. Raghavendra Naik
Surgical Oncologist

Dr. Raghavendra Naik

MBBS, MS (General Surgery), M.Ch (Surgical Oncology)

View Profile
Dr. Mohammed  Imaduddin
Surgical Oncologist

Dr. Mohammed Imaduddin

M.B.B.S, MS (General Surgery), M.Ch (Surgical Oncology)

View Profile
Dr. Vinay Mamidala
Surgical Oncologist

Dr. Vinay Mamidala

MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)

View Profile
Dr. Paila Gowri Naidu
Surgical Oncologist

Dr. Paila Gowri Naidu

MBBS, MS (General Surgery), M.Ch (Surgical Oncology), FMAS

View Profile
Dr. Venkata Sushma P
Radiation Oncologist

Dr. Venkata Sushma P

MBBS, MD (Radiation Oncology)

View Profile
Dr. Kirti Ranjan Mohanty
Radiation Oncologist

Dr. Kirti Ranjan Mohanty

MBBS, MD (Radiation Oncology)

View Profile
Dr. Gangadhar Vajrala
Radiation Oncologist

Dr. Gangadhar Vajrala

MBBS, MD (Radiation Oncology), MPH

View Profile
Dr. Basudev Pokhrel
Hematologist

Dr. Basudev Pokhrel

MBBS, M.D (Immunohematology & Blood Transfusion)

View Profile
Dr. Mohammed Imran
Interventional Radiologist

Dr. Mohammed Imran

View Profile
Dr. Vajja Sandeep Kumar
Surgical Oncologist

Dr. Vajja Sandeep Kumar

MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology

View Profile
Dr. Sridhar Kamani
Surgical Oncologist

Dr. Sridhar Kamani

MBBS, MS (General Surgery), DrNB (Surgical Oncology)

View Profile

Want a specific doctor for your case? Mention them when booking.

Book Free Consultation

You do not have to work this out alone

A 45-minute consultation with a specialist who treats this every week.

Book Free Consultation Call 1800 202 8726

What do the specific terms mean?

Atypical
Cells that look abnormal under the microscope but cannot be classified as cancerous. The word describes an appearance, not a diagnosis. It is often followed by more specific language — atypical cells of undetermined significance, for example — which carries a more precise meaning for that organ and usually leads to further testing.
Borderline
A category between clearly benign and clearly malignant. Most commonly used in gynaecological and thyroid pathology. Borderline tumours may behave unpredictably, which is why they are managed differently from both benign and malignant findings.
Premalignant / precancerous
A change known to be a possible precursor to cancer — meaning the cells sit on a pathway that can lead to malignancy. Detection at this stage is often what allows effective intervention before cancer develops.
Dysplasia
Abnormal cell growth or organisation, classified as low-grade or high-grade. High-grade dysplasia is closer to cancer and requires more urgent assessment. The term is most often seen in results from the cervix, gut lining and respiratory tract.
In situ
Means the abnormal cells are confined to the layer where they started and have not spread into surrounding tissue. Often treated as a very early or premalignant stage. Management depends on the site and grade.
Atypia of undetermined significance
Used when the pathologist cannot confidently place the cells into a clear category. Common in thyroid reports. It typically leads to further testing — repeat sampling or molecular analysis — rather than immediate treatment.

What does monitoring or treatment look like?

The next step depends on the exact finding and the organ. Some results need only regular review with repeat tests at agreed intervals. Others are treated promptly to prevent any chance of progression.

Your specialist will explain whether the plan is surveillance, a procedure to remove affected tissue, or something else.

Ask what the review schedule looks like, what each review will involve, and what change would prompt the approach to shift.

Questions patients and families commonly ask

Does this mean cancer will definitely develop?

No. Many findings in these categories do not progress to cancer, particularly when detected and followed appropriately. Whether your individual result will progress is something pathology alone cannot answer — it depends on the specific finding, the organ, the grade, and how the cells behave under monitoring. Your doctor will explain the trajectory that applies to your result and what would change the plan.

Should we get a second opinion on the pathology?

A second opinion is always reasonable and is especially worth considering when a result is described as borderline or ambiguous, or when the management plan hinges on the exact classification. Bring the original slides and the pathology report rather than asking for a repeat biopsy. A confident specialist is not threatened by a second opinion on a difficult result, and you should not feel that asking for one is overstepping.

Is there a difference between monitoring and doing nothing?

Yes, and this distinction matters. Monitoring means planned tests at agreed intervals with a clear decision point if the cells change. It is a management strategy, not a delay. Doing nothing means no plan and no follow-up. If you are placed on a monitoring pathway, ask what the plan is, when the next test is, and what result would change the approach — before you leave the appointment.

Can diet or lifestyle choices affect whether this progresses?

Some modifiable factors — tobacco use, alcohol, excess weight — have established links to cancer development, and reducing them is supported by guidance from IARC and ICMR. But lifestyle changes cannot reverse a premalignant change that has already developed, and they do not replace the monitoring or treatment your specialist recommends. Ask your doctor directly whether any specific changes are relevant to your finding and organ site.

Do my children or siblings need screening because of my result?

For some findings in some organs, a hereditary element is possible, and your specialist may raise it. For most atypical or borderline results, automatic family screening is not indicated. Ask at your next appointment so the answer is specific to your situation. If a hereditary element is relevant, your doctor can refer you for genetic counselling rather than leaving you to interpret that question alone.

What if the result was wrong and it is actually cancer?

Pathology is the most direct way of classifying tissue, and it is interpreted by trained specialists. But a borderline or ambiguous result by definition sits in uncertain territory. If your symptoms do not fit the result, if a different specialist has a different view, or if something does not feel right to you, say so. A repeat biopsy or a second pathology opinion is a legitimate next step, not an overreaction.

Explore 102 more Your Result, What Comes Next and Support topics

HUB — Who Can Have a Biopsy? Special Situations

HUB — Your Biopsy Confirmed Cancer

All Your Result, What Comes Next and Support →

Next step

Still not sure what applies to you?

Send your reports across and a senior medical oncologist will go through what they mean, what is known, and what the options actually are.

Book Free Consultation Call 1800 202 8726
Common questions

Frequently asked questions

What is the difference between atypical and precancerous?

They are not the same category. Atypical means cells look abnormal but cannot be classified further — it is a descriptive term, not a diagnosis, and it usually leads to more testing. Precancerous describes a specific change with an established relationship to cancer development in that organ. Both require follow-up, but the type of follow-up differs. Your doctor can explain which applies to your report and what the distinction means for your management plan.

How long does it take for a premalignant finding to become cancer?

This varies considerably by finding, organ, grade and individual. Some premalignant changes remain stable for many years. Others progress more quickly. Some never progress at all. Guidance from NCCN and ESMO sets review intervals based on the specific finding and grade, not a single timeline that covers all cases. Your specialist will give you the review schedule that applies to your result and explain what they are watching for at each point.

Should I see an oncologist or stay with my current specialist?

Many premalignant and borderline findings are managed by the specialist who ordered the biopsy — a gynaecologist, gastroenterologist or endocrinologist, for example. An oncologist becomes involved when the risk of progression is considered high, when surveillance shows the cells have changed, or when treatment is needed. If you are unsure who should lead your care, ask directly. A multidisciplinary discussion is appropriate when the path forward is not clear.

Will I need surgery?

Not necessarily. Many premalignant findings are managed without surgery — through surveillance, minor procedures, or ablative treatments depending on the site. Others are removed surgically to prevent progression. The decision depends on the grade, the location, and your overall health. Your specialist will explain the options for your specific result and what each is intended to achieve. No decision needs to be made before you have that conversation.

Is immunotherapy or chemotherapy used for these conditions?

Generally not. These treatments are used for established malignancies. Premalignant and borderline findings are typically managed with surveillance, minor procedures or localised treatment depending on the site. If a finding progresses and is reclassified as malignant, the treatment approach changes accordingly. Your specialist will explain what treatment, if any, is appropriate at your current stage.

What should I tell my family about this result?

There is no single right answer, and the decision is yours. What helps most families is a clear, accurate summary: that this is not a cancer diagnosis, that it is being managed, and that there is a follow-up plan. Avoid framing it as nothing to worry about if follow-up is genuinely needed, and avoid catastrophising in the other direction. The facts — what the result is, what happens next, when the review is — are the steadiest thing to share.

Full index

Browse all 701 biopsy topics

Every page in this section, grouped by the part of the journey it belongs to. Pick a group to see what is in it.

What Is a Biopsy?

What Is a Biopsy? Everything You Need to Know →

Types of Biopsy Compared

Which Biopsy Will You Have? Techniques Compared →

Preparing for a Biopsy

What to Expect on the Day of Your Biopsy →

Recovery and Aftercare

After a Biopsy: Recovery, Aftercare and Warning Signs →

Biopsy by Body Part

Biopsy by Body Part: What to Expect at Each Site →

Understanding Your Report

How to Read a Biopsy Report: Terms Explained →

IHC and Molecular Markers

IHC and Molecular Markers on a Biopsy: What They Mean →

Grading and Scoring Systems

Cytology & Prostate Scoring Systems Explained →

How Accurate Is a Biopsy?

How Accurate Is a Biopsy? Errors and Second Opinions →

If Your Result Is Benign

Your Biopsy Is Benign: What It Means and What Comes Next →

Call now Book free consultation